【私募调研记录】复胜资产调研博瑞医药

Group 1 - The core viewpoint of the news is that Fusheng Asset has conducted research on the listed company Borui Pharmaceutical, focusing on the collaboration with China Resources Sanjiu to commercialize the BGM0504 product in China quickly [1] - Borui Pharmaceutical's BGM0504 product is expected to demonstrate its advantages through more clinical trials, and it has global competitiveness with plans for international expansion [1] - The BGM1812 product is characterized by fat reduction without muscle loss and is currently advancing IND applications in both China and the United States [1] Group 2 - Fusheng Asset Management, established in 2015, is one of the first research-driven private equity fund management companies in China, with a pure equity management scale exceeding 60 billion [2] - The core investment research team at Fusheng Asset has over 16 years of investment experience across mainland China, Hong Kong, and the United States, with fund managers having top-tier public fund investment experience [2] - The company emphasizes sustainable investment and aims to achieve long-term stable returns for investors, having received multiple awards for its performance in the private equity sector [2]